• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Synribo (omacetaxine mepesuccinate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Synribo (omacetaxine mepesuccinate)

  • Profile

Profile

Contact Information

Contact: Teva Pharmaceuticals
Website: http://www.synribohcp.com/

Currently Enrolling Trials

    Show More

    General Information

    Synribo (omacetaxine mepesuccinate) is a cephalotaxine ester. It is a protein synthesis inhibitor and is independent of direct Bcr-Abl binding.

    Synribo is specifically approved for the treatment of adults with chronic or accelerated phase chronic myeloid leukemia with resistance and/or intolerance to two or more tyrosine kinase inhibitors.

    Mechanism of Action

    Synribo (omacetaxine mepesuccinate) is a cephalotaxine ester. It is a protein synthesis inhibitor and is independent of direct Bcr-Abl binding. Omacetaxine mepesuccinate binds to the A-site cleft in the peptidyl-transferase center of the large ribosomal subunit from a strain of archaeabacteria. In vitro, omacetaxine mepesuccinate reduced protein levels of the Bcr-Abl oncoprotein and Mcl-1, an anti-apoptotic Bcl-2 family member.

    Side Effects

    Adverse events associated with the use of Synribo may include, but are not limited to, the following:

    • thrombocytopenia
    • anemia
    • neutropenia
    • diarrhea
    • nausea
    • fatigue
    • asthenia
    • injection site reaction
    • pyrexia
    • infection
    • lymphopenia

    Dosing/Administration

    Synribo is supplied as a solution for subcutaneous administration. The recommended initial dose of the drug is as follows: Induction schedule: 1.25 mg/m2 administered subcutaneously twice daily for 14 consecutive days every 28 days, over a 28-day cycle. Cycles should be repeated every 28 days until patients achieve a hematologic response. Maintenance dosing: 1.25 mg/m2 administered subcutaneously twice daily for seven consecutive days every 28 days, over a 28-day cycle. Treatment should continue as long as patients are clinically benefiting from therapy.

    Clinical Trial Results

    The FDA approval of Synribo was based on a combined cohort of adults with CML from two trials. The combined cohort consisted of subjects who had received two or more approved TKIs and had, at a minimum, documented evidence of resistance or intolerance to dasatinib and/or nilotinib. The subjects were treated with omacetaxine mepesuccinate at a dose of 1.25 mg/m2 administered subcutaneously twice daily for 14 consecutive days, every 28 days (induction cycle). Responders were then treated with the same dose and twice daily schedule for seven consecutive days every 28 days (maintenance cycle) for up to 24 months.

    Chronic Phase CML
    A total of 76 subjects were included in the efficacy analysis. The efficacy endpoint was based on major cytogenetic response (MCyR). Fourteen subjects (18.4 percent) achieved MCyR; 7.9 percent achieved confirmed complete cytogenic response and 3.9 percent achieved confirmed partial cytogenic response. The mean time to MCyR onset was 3.5 months and the median duration of MCyR was 12.5 months.

    Accelerated Phase CML
    A total of 35 subjects were included in the efficacy analysis. The efficacy endpoint was based on major cytogenetic response (MCyR) and MaHR (complete hematologic response [CHR] or no evidence of leukemia [NEL]. Five subjects (14.3 percent) achieved MaHR; four subjects (11.4 percent) CHR and one (2.9 percent) NEL. Zero subjects achieved MCyR. The mean time to response onset in the five subjects was 2.3 months and the median duration of MaHR was 4.7 months.

     

    Approval Date: 2012-10-01
    Company Name: Teva Pharmaceutical
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing